Last updated: August 27, 2026

Haloperidol Intensol is a generic oral concentrate containing haloperidol, an older first-generation antipsychotic. Its commercial value is driven by specialized demand rather than broad branded-drug pricing. The product has no meaningful remaining compound-patent protection, no apparent market exclusivity, and limited public revenue disclosure. Its main commercial risks are generic price compression, supply interruption, manufacturing concentration and substitution by tablets, compounded liquids, injectable haloperidol and newer antipsychotics.

What is Haloperidol Intensol and how is it used?

Haloperidol Intensol is a 2 mg/mL oral solution concentrate of haloperidol. It is administered in small measured volumes and is intended for patients who cannot reliably swallow tablets or who require flexible dose titration. The FDA labeling identifies schizophrenia and Tourette's disorder among its indications. Haloperidol is also used clinically in several settings outside the core labeled indications, including acute agitation, delirium and palliative-care symptom management, subject to clinical judgment and applicable prescribing rules.[1]

Product attribute	Haloperidol Intensol
Active ingredient	Haloperidol
Dosage form	Oral solution concentrate
Strength	2 mg/mL
Therapeutic class	First-generation antipsychotic
Route	Oral
Prescription status	Prescription only
Primary users	Psychiatry, hospitals, long-term care, hospice and palliative care
Reference pharmacology	Dopamine D2 receptor antagonism
Key safety risks	Tardive dyskinesia, extrapyramidal symptoms, QT prolongation, neuroleptic malignant syndrome and increased mortality in elderly patients with dementia-related psychosis
Commercial category	Generic specialty presentation, not a protected branded innovation

The concentrate format has practical value in patients with dysphagia, impaired cooperation, feeding-tube requirements or the need for precise low-volume dosing. Its addressable market is materially smaller than the market for conventional haloperidol tablets.

What FDA regulatory status does Haloperidol Intensol have?

Haloperidol Intensol is marketed as an abbreviated new drug application product rather than as a newly developed molecular entity. The FDA-approved product relies on the established safety and efficacy record for haloperidol and demonstrates pharmaceutical equivalence and bioequivalence through the applicable generic-drug pathway.[2]

The product’s regulatory profile has several implications:

The applicant does not bear the full clinical-development cost associated with a new antipsychotic.
FDA approval does not create meaningful long-term commercial exclusivity.
Multiple haloperidol dosage forms can compete for the same patients.
Manufacturing, stability, dose-measurement and container-closure controls remain commercially important even though the active ingredient is old.

The FDA labeling includes a boxed warning concerning increased mortality in elderly patients with dementia-related psychosis. The product is not approved for that use. The label also warns about tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation and other serious adverse reactions.[1]

What patents protect Haloperidol Intensol?

No commercially significant unexpired composition-of-matter patent protects haloperidol. The molecule was discovered and commercialized many decades ago, and any original compound protection expired long before the current generic market.

The relevant intellectual-property position is therefore limited to potential formulation, process, packaging or method-of-use rights. Those rights do not appear to create a meaningful market barrier for Haloperidol Intensol.

IP category	Commercial position
Haloperidol compound patent	Expired
Core antipsychotic indication protection	Expired or unavailable as a current barrier
Generic product exclusivity	No material exclusivity identified
Orange Book patent protection	No current patent barrier expected for the generic oral concentrate
Formulation patents	No publicly identified formulation right appears to block ordinary generic competition
Method-of-use patents	No material exclusivity identified for the labeled uses
Manufacturing patents	Potentially relevant only to a specific process or supplier, not to the molecule generally

The FDA Orange Book remains the principal source for listed patents and regulatory exclusivity associated with approved products.[3] For an old generic product such as Haloperidol Intensol, the commercial question is less about patent enforcement and more about whether competing applicants can obtain approval and secure reliable supply.

When does Haloperidol Intensol lose exclusivity?

Haloperidol Intensol does not have a conventional future loss-of-exclusivity date comparable to a protected branded medicine. Its commercial exclusivity was effectively absent when it entered the generic market.

Exclusivity type	Status
New chemical entity exclusivity	Not applicable
New clinical investigation exclusivity	Not identified
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not identified
Generic 180-day Paragraph IV exclusivity	No material current barrier identified
Patent-based exclusivity	Expired or not commercially relevant

This distinction matters for forecasting. Revenue cannot be modeled around a predictable patent cliff. The product is already exposed to generic competition, contracting pressure and substitution.

How many patents cover Haloperidol Intensol?

There is no material patent estate publicly associated with Haloperidol Intensol that would support a protected franchise. The product may be manufactured under internal process know-how, quality systems, trade secrets or supplier agreements, but those protections are different from an Orange Book-listed patent estate.

For investors and licensing teams, the practical conclusion is that Haloperidol Intensol has low patent strength and low litigation leverage. A competitor would generally focus on FDA approval, manufacturing readiness, distribution access and contracting rather than patent invalidity litigation.

Which companies compete with Haloperidol Intensol?

Competition comes from both direct haloperidol products and therapeutic substitutes.

Direct dosage-form competition

The closest alternatives include:

Haloperidol tablets in multiple strengths
Haloperidol oral solutions or concentrates from other approved manufacturers
Hospital-prepared or pharmacy-compounded liquid formulations, where legally and operationally appropriate
Haloperidol lactate injection for patients requiring parenteral treatment
Haloperidol decanoate injection for long-acting maintenance therapy

The direct oral-concentrate market is narrower than the overall haloperidol market. A product can maintain demand even with low unit volume if it is included in hospital formularies, hospice protocols or long-term-care medication systems.

Therapeutic substitutes

Substitution can occur with other antipsychotics, including risperidone, olanzapine, quetiapine, aripiprazole, chlorpromazine and certain liquid formulations. The choice depends on indication, route, adverse-effect profile, formulary policy, patient age, renal and hepatic status, sedation requirements and prescriber preference.

No competing product is pharmacologically identical in all practical respects. Haloperidol remains attractive where clinicians need a familiar, inexpensive antipsychotic with oral, injectable and long-acting presentations.

What formulations are protected by Haloperidol Intensol?

The main commercial differentiation is the liquid-concentrate presentation, not patent protection. The 2 mg/mL strength permits dose delivery in small volumes but creates handling and medication-error considerations.

The product’s formulation economics depend on:

Stable concentration over shelf life
Accurate dosing devices
Container compatibility
Taste and patient acceptance
Alcohol and excipient tolerability
Packaging that reduces accidental administration errors
Consistent availability through wholesalers and institutional channels

These attributes can create practical switching costs without creating legally enforceable exclusivity. In hospitals and hospice networks, a reliable product may remain preferred because changing a formulary item requires new protocols, staff education and medication-system updates.

What generic entry risks exist for Haloperidol Intensol?

Generic entry risk is high because the active ingredient and dosage form are technically established. A new applicant would not need to develop a new clinical program. The principal barriers are commercial scale, manufacturing economics and market size.

Paragraph IV challenges

A Paragraph IV challenge is unlikely to be commercially central because there is no apparent blocking patent estate. A generic applicant would normally pursue an ANDA with a Paragraph III certification, a Paragraph IV certification only if an unexpired listed patent were relevant, or another certification pathway based on the Orange Book record.[2,3]

The absence of meaningful patent protection reduces litigation risk but also eliminates the ability of the incumbent to delay entry through patent enforcement. If a competitor launches, the incumbent’s defenses would more likely involve price, supply reliability, customer relationships and regulatory quality than patent litigation.

Generic launch scenarios

Scenario	Market effect	Probability assessment
One additional oral-concentrate supplier	Moderate price pressure; improved supply resilience	Commercially plausible
Several new suppliers	Significant price erosion and lower incumbent share	Possible if margins support entry
Incumbent manufacturing interruption	Temporary shortages and substitution into tablets or compounded products	Material operating risk
Hospital or hospice formulary conversion	Rapid volume loss for a single supplier	Possible in concentrated accounts
Broader shift to newer antipsychotics	Gradual demand erosion	Indication-dependent
Stable institutional demand	Flat volume with continued low-price competition	Most likely base case

What litigation and settlement agreements affect Haloperidol Intensol?

No major active patent litigation or high-value settlement agreement is publicly associated with Haloperidol Intensol as a standalone product. That outcome is consistent with the product’s age, generic status and limited patent value.

The more relevant legal exposure lies in ordinary generic-drug compliance:

ANDA approval and supplements
Current good manufacturing practice compliance
Product-quality investigations
Labeling compliance
Controlled-substance and pharmacy-distribution rules where applicable
Product-liability claims involving dosing errors or adverse reactions
Recalls caused by contamination, potency or packaging defects

For commercial diligence, the absence of blockbuster patent litigation should not be interpreted as the absence of operational risk. A manufacturing warning letter or shortage can affect revenue faster than a patent dispute.

How strong is the patent estate for Haloperidol Intensol?

The patent estate is weak by branded-pharmaceutical standards and offers little licensing value. Its strength can be summarized as follows:

Dimension	Assessment
Composition-of-matter protection	None of commercial relevance
Formulation protection	Limited or not publicly material
Method-of-use protection	Limited or not publicly material
Patent litigation leverage	Low
Regulatory exclusivity	Low
Manufacturing know-how value	Moderate at the supplier level
Brand differentiation	Limited
Supply-chain value	Potentially meaningful

The most defensible asset is not the molecule. It is the ability to produce a compliant, stable, accurately packaged liquid and distribute it without interruption.

What is the commercial and financial trajectory of Haloperidol Intensol?

Standalone revenue for Haloperidol Intensol is not separately disclosed in public filings. Manufacturers typically report at segment or portfolio level rather than by individual low-volume generic product. The product’s financial trajectory must therefore be assessed through market structure rather than reported product sales.

Revenue drivers

The principal revenue drivers are:

Institutional demand from hospitals, long-term-care facilities and hospice providers
Availability of the oral concentrate relative to tablets and injections
Number of approved competitors
Wholesale acquisition and contract pricing
Product shortages affecting competing suppliers
Formulary placement
Prescriber familiarity
Patient populations requiring liquid administration

Margin profile

The product likely has a lower gross-margin ceiling than a protected branded drug because:

Haloperidol is inexpensive to manufacture as an active ingredient.
Generic buyers negotiate aggressively.
The market has limited differentiation.
Regulatory and quality costs are spread over relatively small volumes.
A liquid concentrate requires packaging and stability controls.
Institutional customers can switch suppliers when contracts change.

Margins can improve during shortages or when the product has few active suppliers. Those gains are vulnerable to new entrants and normalizing supply.

Financial trajectory by scenario

Period	Base-case outlook	Main variables
Near term	Stable to modestly declining revenue	Mature demand, price pressure, institutional use
Medium term	Low growth or gradual erosion	Additional generic entry and substitution
Upside case	Temporary revenue increase	Competitor shortage, contract win or supply disruption
Downside case	Sharp volume and price decline	New supplier launches, delisting or manufacturing interruption

The product is more likely to generate dependable niche cash flow than substantial growth. It can have strategic value inside a broader generic portfolio because it uses established regulatory infrastructure and may benefit from recurring institutional demand.

How does Haloperidol Intensol compare with newer antipsychotics?

Factor	Haloperidol Intensol	Newer atypical antipsychotics
Patent protection	None of commercial significance	Varies by product; many are also generic
Price	Usually low	Ranges from low generic pricing to high branded pricing
Liquid dosing	Available in concentrate form	Available for selected products
Extrapyramidal-risk profile	Higher concern	Often lower, but product-specific
Sedation and metabolic effects	Product-specific; generally less metabolic liability than many atypicals	Metabolic risk can be substantial for some agents
Clinical familiarity	Long-established	High for leading products
Institutional use	Strong in selected settings	Strong across broader chronic-treatment markets
Revenue growth potential	Limited	Higher for differentiated or protected products

Haloperidol Intensol competes effectively when cost, familiarity, rapid titration and liquid administration are priorities. It is less advantaged when clinicians prioritize newer safety profiles or long-term tolerability.

What geographic markets and manufacturing barriers matter?

The United States is the key reference market for the product’s FDA-approved labeling and Orange Book status. Comparable haloperidol liquid products may be marketed under different names, strengths or regulatory pathways in Europe, Canada, Asia and other regions. U.S. FDA status should not be treated as evidence of approval in those jurisdictions.

Manufacturing barriers include:

Validated liquid formulation processes
Raw-material qualification
Stability data
Accurate dose-delivery packaging
Alcohol and excipient controls
FDA inspection readiness
Reliable contract-manufacturing capacity
Wholesaler and institutional distribution

These barriers are operational rather than patent-based. They can limit entry into a small market, but they do not support premium pricing indefinitely.

Key Takeaways

Haloperidol Intensol is a 2 mg/mL oral haloperidol concentrate for specialized liquid-dosing needs.
The product has no meaningful remaining compound-patent protection.
No significant current Orange Book patent or exclusivity barrier is expected to protect the generic product.
Paragraph IV litigation and settlement risk are low compared with protected branded medicines.
Direct competition includes haloperidol tablets, oral liquids, injections and compounded preparations.
Newer antipsychotics create therapeutic substitution risk, but haloperidol retains institutional and palliative-care utility.
Standalone product revenue is not publicly disclosed.
The likely financial profile is mature, low-growth and price-sensitive, with temporary upside during competitor shortages.
The most important defensible advantages are supply reliability, manufacturing compliance, formulary access and distribution relationships.
Revenue is exposed to generic entry, price erosion, product quality events and institutional formulary changes.

Frequently Asked Questions

Is Haloperidol Intensol a branded drug or a generic drug?

Haloperidol Intensol is marketed as a generic haloperidol oral concentrate. The commercial name identifies the dosage form and product presentation, not a current patented innovation.

Does Haloperidol Intensol have a patent expiration date?

There is no commercially meaningful future compound-patent expiration date for haloperidol. The molecule’s original patent protection expired decades ago.

Can pharmacies substitute haloperidol tablets for Haloperidol Intensol?

Substitution depends on the prescribed dosage form, state law, pharmacy policy and clinical appropriateness. Tablets and oral concentrate are not automatically interchangeable in every prescribing or dispensing context.

Is Haloperidol Intensol included in Medicare reimbursement?

Coverage and reimbursement depend on the payer, formulary, dispensing channel, National Drug Code and patient setting. Medicare Part D, Medicare Advantage and institutional reimbursement can apply different rules.

What would most increase the value of a Haloperidol Intensol supplier?

The largest potential value drivers are durable hospital or hospice contracts, shortage-driven market share, additional approved liquid products, reliable manufacturing capacity and a broader generic portfolio that lowers distribution and regulatory overhead.

References

U.S. Food and Drug Administration. (2023). Haloperidol Intensol: Prescribing information. DailyMed.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and generic drug regulatory pathways. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	11
Patent Applications:	394
DailyMed Link:	HALOPERIDOL INTENSOL at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	HALOPERIDOL INTENSOL	haloperidol lactate	CONCENTRATE;ORAL	072045-001	Apr 12, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

HALOPERIDOL INTENSOL Drug Patent Profile

Which patents cover Haloperidol Intensol, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for HALOPERIDOL INTENSOL

US Patents and Regulatory Information for HALOPERIDOL INTENSOL

Haloperidol Intensol Market Dynamics, Patent Position and Financial Trajectory